A A A

Alimera Sciences to Report Third Quarter 2018 Results November 5, 2018

Alimera Sciences to Report Third Quarter 2018 Results November 5, 2018

Oct 23, 2018

ATLANTA, GA / ACCESSWIRE / October 23, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the third quarter ended September 30, 2018, after the close of the financial markets on Monday, November 5, 2018.

An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 9:00 AM ET, on Tuesday, November 6, 2018. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Details

Conference Date: Tuesday, November 6, 2018, 9:00 AM ET
Conference Dial-In: 877.269.7756
International Dial-In: 201.689.7817
Conference Call Name: Alimera Sciences (ALIM) Third Quarter 2018 Results Call
Webcast Registration: Click Here

Following the live call, a replay will be available for six months on the Company's website, www.alimerasiences.com, in the "Investor Relations" section.

About Alimera Sciences, Inc.

www.alimerasciences.com

Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in Alimera's product and development portfolio. For more information, please visit www.alimerasciences.com.

For press inquiries:
Katie Brazel
for Alimera Sciences 
404-317-8361
kbrazel@bellsouth.net

For investor inquiries:
Rich Cockrell
CG Capital
for Alimera Sciences
877-889-1972
investorrelations@cg.capital

SOURCE: Alimera Sciences, Inc.